Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

被引：3

作者：

Bersanelli, Melissa ^{[1
]}

Gnetti, Letizia ^{[2
]}

Azzoni, Cinzia ^{[2
]}

Bottarelli, Lorena ^{[2
]}

Sverzellati, Nicola ^{[3
]}

Campanini, Nicoletta ^{[2
]}

Varotti, Elena ^{[2
]}

Corrado, Michele ^{[3
]}

Parziale, Raffaele ^{[3
]}

Rapacchi, Elena ^{[1
]}

Caruso, Giuseppe ^{[1
]}

Leonardi, Francesco ^{[1
]}

Silini, Enrico Maria ^{[2
]}

Buti, Sebastiano ^{[1
]}

机构：

[1] Univ Hosp Parma, Med Oncol, Via Gramsci 14, I-43126 Parma, Italy

[2] Univ Hosp Parma, Pathol Anat Unit, Via Gramsci 14, I-43126 Parma, Italy

[3] Univ Hosp Parma, Radiol Unit, Via Gramsci 14, I-43126 Parma, Italy

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 09期

关键词：

FHIT; loss of heterozygosity; renal cell carcinoma; SPORADIC BREAST-CANCER; CLEAR-CELL CARCINOMA; MISMATCH-REPAIR; MICROSATELLITE INSTABILITY; OVARIAN-CANCER; BRCA2; VHL; 3P; TUMORIGENESIS; GUIDELINES;

D O I：

10.2217/imt-2017-0160

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.

引用

页码：743 / +

页数：11

共 31 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
Abkevich, V.
Timms, K. M.
Hennessy, B. T.
Potter, J.
Carey, M. S.
Meyer, L. A.
Smith-McCune, K.
Broaddus, R.
Lu, K. H.
Chen, J.
Tran, T. V.
Williams, D.
Iliev, D.
Jammulapati, S.
FitzGerald, L. M.
Krivak, T.
DeLoia, J. A.
Gutin, A.
Mills, G. B.
Lanchbury, J. S.
[J]. BRITISH JOURNAL OF CANCER, 2012, 107 (10) : 1776 - 1782
[2] Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma
Alimov, A
Kost-Alimova, M
Liu, J
Li, CD
Bergerheim, U
Imreh, S
Klein, G
Zabarovsky, ER
[J]. ONCOGENE, 2000, 19 (11) : 1392 - 1399
[3] Microsatellite instability and hMLH1 and hMSH2 expression in renal tumors
Altavilla, Giuseppe
Fassan, Matteo
Busatto, Graziella
Orsolan, Martina
Giacomelli, Luciano
[J]. ONCOLOGY REPORTS, 2010, 24 (04) : 927 - 932
[4] [Anonymous], 2016, J CLIN ONCOL S
[5] Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer
Beckmann, MW
Picard, F
An, HX
vanRoeyen, CRC
Dominik, SI
Mosny, DS
Schnurch, HG
Bender, HG
Niederacher, D
[J]. BRITISH JOURNAL OF CANCER, 1996, 73 (10) : 1220 - 1226
[6] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Zachary R.
Connelly, Caitlin F.
Fabrizio, David
Gay, Laurie
Ali, Siraj M.
Ennis, Riley
Schrock, Alexa
Campbell, Brittany
Shlien, Adam
Chmielecki, Juliann
Huang, Franklin
He, Yuting
Sun, James
Tabori, Uri
Kennedy, Mark
Lieber, Daniel S.
Roels, Steven
White, Jared
Otto, Geoffrey A.
Ross, Jeffrey S.
Garraway, Levi
Miller, Vincent A.
Stephens, Phillip J.
Frampton, Garrett M.
[J]. GENOME MEDICINE, 2017, 9
[7] Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO
[8] 2-#
[9] Department of Health and Human Services, 2010, COMM TERM CRIT ADV E
[10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Eisenhauer, E. A.
Therasse, P.
Bogaerts, J.
Schwartz, L. H.
Sargent, D.
Ford, R.
Dancey, J.
Arbuck, S.
Gwyther, S.
Mooney, M.
Rubinstein, L.
Shankar, L.
Dodd, L.
Kaplan, R.
Lacombe, D.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247

← 1 2 3 4 →